table of content
1 Introduction to Research & Analysis Reports
1.1 PD-1&PD-L1 Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global PD-1&PD-L1 Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global PD-1&PD-L1 Immunotherapy Overall Market Size
2.1 Global PD-1&PD-L1 Immunotherapy Market Size: 2022 VS 2030
2.2 Global PD-1&PD-L1 Immunotherapy Revenue, Prospects & Forecasts: 2018-2030
2.3 Global PD-1&PD-L1 Immunotherapy Sales: 2018-2030
3 Company Landscape
3.1 Top PD-1&PD-L1 Immunotherapy Players in Global Market
3.2 Top Global PD-1&PD-L1 Immunotherapy Companies Ranked by Revenue
3.3 Global PD-1&PD-L1 Immunotherapy Revenue by Companies
3.4 Global PD-1&PD-L1 Immunotherapy Sales by Companies
3.5 Global PD-1&PD-L1 Immunotherapy Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 PD-1&PD-L1 Immunotherapy Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers PD-1&PD-L1 Immunotherapy Product Type
3.8 Tier 1, Tier 2 and Tier 3 PD-1&PD-L1 Immunotherapy Players in Global Market
3.8.1 List of Global Tier 1 PD-1&PD-L1 Immunotherapy Companies
3.8.2 List of Global Tier 2 and Tier 3 PD-1&PD-L1 Immunotherapy Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global PD-1&PD-L1 Immunotherapy Market Size Markets, 2022 & 2030
4.1.2 PD-1 Inhibitors
4.1.3 PD-L1 Inhibitors
4.2 By Type - Global PD-1&PD-L1 Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global PD-1&PD-L1 Immunotherapy Revenue, 2018-2023
4.2.2 By Type - Global PD-1&PD-L1 Immunotherapy Revenue, 2024-2030
4.2.3 By Type - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
4.3 By Type - Global PD-1&PD-L1 Immunotherapy Sales & Forecasts
4.3.1 By Type - Global PD-1&PD-L1 Immunotherapy Sales, 2018-2023
4.3.2 By Type - Global PD-1&PD-L1 Immunotherapy Sales, 2024-2030
4.3.3 By Type - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
4.4 By Type - Global PD-1&PD-L1 Immunotherapy Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global PD-1&PD-L1 Immunotherapy Market Size, 2022 & 2030
5.1.2 Non-Small Cell Lung Cancer
5.1.3 Esophageal Cancer
5.1.4 Urothelial Carcinoma
5.1.5 Hepatocellular Carcinoma
5.1.6 Small Cell Lung Cancer
5.1.7 Others
5.2 By Application - Global PD-1&PD-L1 Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global PD-1&PD-L1 Immunotherapy Revenue, 2018-2023
5.2.2 By Application - Global PD-1&PD-L1 Immunotherapy Revenue, 2024-2030
5.2.3 By Application - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
5.3 By Application - Global PD-1&PD-L1 Immunotherapy Sales & Forecasts
5.3.1 By Application - Global PD-1&PD-L1 Immunotherapy Sales, 2018-2023
5.3.2 By Application - Global PD-1&PD-L1 Immunotherapy Sales, 2024-2030
5.3.3 By Application - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
5.4 By Application - Global PD-1&PD-L1 Immunotherapy Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global PD-1&PD-L1 Immunotherapy Market Size, 2022 & 2030
6.2 By Region - Global PD-1&PD-L1 Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global PD-1&PD-L1 Immunotherapy Revenue, 2018-2023
6.2.2 By Region - Global PD-1&PD-L1 Immunotherapy Revenue, 2024-2030
6.2.3 By Region - Global PD-1&PD-L1 Immunotherapy Revenue Market Share, 2018-2030
6.3 By Region - Global PD-1&PD-L1 Immunotherapy Sales & Forecasts
6.3.1 By Region - Global PD-1&PD-L1 Immunotherapy Sales, 2018-2023
6.3.2 By Region - Global PD-1&PD-L1 Immunotherapy Sales, 2024-2030
6.3.3 By Region - Global PD-1&PD-L1 Immunotherapy Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.4.2 By Country - North America PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.4.3 US PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.4.4 Canada PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.4.5 Mexico PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.5.2 By Country - Europe PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.5.3 Germany PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.4 France PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.5 U.K. PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.6 Italy PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.7 Russia PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.8 Nordic Countries PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.5.9 Benelux PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.6.2 By Region - Asia PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.6.3 China PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6.4 Japan PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6.5 South Korea PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6.6 Southeast Asia PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.6.7 India PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.7.2 By Country - South America PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.7.3 Brazil PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.7.4 Argentina PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa PD-1&PD-L1 Immunotherapy Sales, 2018-2030
6.8.3 Turkey PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.8.4 Israel PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.8.5 Saudi Arabia PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
6.8.6 UAE PD-1&PD-L1 Immunotherapy Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 AstraZeneca Plc
7.1.1 AstraZeneca Plc Company Summary
7.1.2 AstraZeneca Plc Business Overview
7.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Major Product Offerings
7.1.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.1.5 AstraZeneca Plc Key News & Latest Developments
7.2 BeiGene, Ltd.
7.2.1 BeiGene, Ltd. Company Summary
7.2.2 BeiGene, Ltd. Business Overview
7.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.2.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.2.5 BeiGene, Ltd. Key News & Latest Developments
7.3 Bristol-Myers Squibb Company
7.3.1 Bristol-Myers Squibb Company Company Summary
7.3.2 Bristol-Myers Squibb Company Business Overview
7.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Major Product Offerings
7.3.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.3.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
7.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Summary
7.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview
7.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Key News & Latest Developments
7.5 Eli Lilly & Company
7.5.1 Eli Lilly & Company Company Summary
7.5.2 Eli Lilly & Company Business Overview
7.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Major Product Offerings
7.5.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.5.5 Eli Lilly & Company Key News & Latest Developments
7.6 F. Hoffmann-La Roche Ltd
7.6.1 F. Hoffmann-La Roche Ltd Company Summary
7.6.2 F. Hoffmann-La Roche Ltd Business Overview
7.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Major Product Offerings
7.6.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.6.5 F. Hoffmann-La Roche Ltd Key News & Latest Developments
7.7 GlaxoSmithKline plc
7.7.1 GlaxoSmithKline plc Company Summary
7.7.2 GlaxoSmithKline plc Business Overview
7.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Major Product Offerings
7.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.7.5 GlaxoSmithKline plc Key News & Latest Developments
7.8 Innovent Biologics, Inc.
7.8.1 Innovent Biologics, Inc. Company Summary
7.8.2 Innovent Biologics, Inc. Business Overview
7.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.8.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.8.5 Innovent Biologics, Inc. Key News & Latest Developments
7.9 Jiangsu HengRui Medicine Co., Ltd.
7.9.1 Jiangsu HengRui Medicine Co., Ltd. Company Summary
7.9.2 Jiangsu HengRui Medicine Co., Ltd. Business Overview
7.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.9.5 Jiangsu HengRui Medicine Co., Ltd. Key News & Latest Developments
7.10 Merck & Co., Inc.
7.10.1 Merck & Co., Inc. Company Summary
7.10.2 Merck & Co., Inc. Business Overview
7.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.10.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.10.5 Merck & Co., Inc. Key News & Latest Developments
7.11 Novartis AG
7.11.1 Novartis AG Company Summary
7.11.2 Novartis AG PD-1&PD-L1 Immunotherapy Business Overview
7.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Major Product Offerings
7.11.4 Novartis AG PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.11.5 Novartis AG Key News & Latest Developments
7.12 Pfizer Inc.
7.12.1 Pfizer Inc. Company Summary
7.12.2 Pfizer Inc. PD-1&PD-L1 Immunotherapy Business Overview
7.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.12.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.12.5 Pfizer Inc. Key News & Latest Developments
7.13 Regeneron Pharmaceuticals Inc.
7.13.1 Regeneron Pharmaceuticals Inc. Company Summary
7.13.2 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Business Overview
7.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.13.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.13.5 Regeneron Pharmaceuticals Inc. Key News & Latest Developments
7.14 Sanofi S.A.
7.14.1 Sanofi S.A. Company Summary
7.14.2 Sanofi S.A. Business Overview
7.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Major Product Offerings
7.14.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales and Revenue in Global (2018-2023)
7.14.5 Sanofi S.A. Key News & Latest Developments
8 Global PD-1&PD-L1 Immunotherapy Production Capacity, Analysis
8.1 Global PD-1&PD-L1 Immunotherapy Production Capacity, 2018-2030
8.2 PD-1&PD-L1 Immunotherapy Production Capacity of Key Manufacturers in Global Market
8.3 Global PD-1&PD-L1 Immunotherapy Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 PD-1&PD-L1 Immunotherapy Supply Chain Analysis
10.1 PD-1&PD-L1 Immunotherapy Industry Value Chain
10.2 PD-1&PD-L1 Immunotherapy Upstream Market
10.3 PD-1&PD-L1 Immunotherapy Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 PD-1&PD-L1 Immunotherapy Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
